THE USE OF SUNITINIB IN PANCREATIC NEUROENDOCRINE TUMORS: EXPERIENCE OF THE DEPARTMENT OF CHEMOTHERAPY FSBI RORC N.A. N.N. BLOKHIN OF RMH
- Authors: Odintsova A.S1, Gorbunova V.A1, Orel N.F1, Markovich A.A1, Kuzminov A.E1, Polozkova S.A1, Emelyanova G.S1, Kuznetsova A.A1
-
Affiliations:
- Issue: No 17 (2016)
- Pages: 44-48
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289341
- ID: 289341
Cite item
Abstract
Keywords
Full Text
About the authors
A. S Odintsova
Email: odincova.anastas@mail.ru
FSBI RORC n.a. N.N. Blokhin of RMH PhD, Oncologist at the Department of Chemotherapy Moscow
V. A Gorbunova
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
N. F Orel
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
A. A Markovich
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
A. E Kuzminov
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
S. A Polozkova
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
G. S Emelyanova
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
A. A Kuznetsova
FSBI RORC n.a. N.N. Blokhin of RMH Moscow
References
- Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. 2003;9:327-37.
- Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., Raymond E. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. J. Clin. Oncol. 2006;24(1): 25-35.
- Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I. Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patents with metastatic renal cell carcinoma. J. Clin. Oncol. 2006;24(1): 16-24.
- Motzer R.J., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferonalfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proceedings ASCO 2006, abstr. LBA3.
- Rini B.I., et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). Proceedings ASCO 2006, abstr. 4522.
- Demetri G.D., et al. SU 11248, a multitargeted tyrosine kinase inhibitor, can overcome imatinib -resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor. Proceedings ASCO 2004, abstr. 3001.
- Morgan J.A., et al. Patients with Imatinib-mesylate-resistant GIST exhibit durable responses to Sunitinib malate (SU11248). 17th ICACT, 2008; poster session.
- Demetri G.D., et al. Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate (IM) therapy in a phase III trial. Advances in the Treatment of Esophageal and Gastric Cancers, abstr. 8.
- Beaumont J.L., et al. Efficacy and Patient-Reported Outcomes of Sunitinib Malate (SU11248) in Three Phase II Trials in advanced Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, and Neuroendocrine Tumor. 17th ICACT, 2008; poster session.
- Miller K.D., et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proceedings ASCO 2005, abstr. 563.
- Raymond E., Faivre S., Hammel P., Ruszniewski P. Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol. 2009;4(4):253-54.
- Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011;364(6):501-13.
- Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M., Fuchs C.S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2008;26(20):3403-10.
- Frilling A., Akerström G., Falconi M., Pavel M., Ramos J., Kidd M., Modlin I.M. Neuroendocrine tumor disease: an evolving landscape. Endocr. Relat Cancer. 2012;19:163-85.